Antibody-drug conjugate trial starts vs Alzheimer's disease drug trial starts
In 2025, antibody-drug conjugate trial starts worldwide stood at 349, against 78 for alzheimer's disease drug trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Antibody-drug conjugate trial starts and Alzheimer's disease drug trial starts
Unit: count · 12 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Antibody-drug conjugate trial starts | 2025 | Actual | 349 |
| Antibody-drug conjugate trial starts | 2024 | Actual | 282 |
| Antibody-drug conjugate trial starts | 2023 | Actual | 233 |
| Antibody-drug conjugate trial starts | 2022 | Actual | 176 |
| Antibody-drug conjugate trial starts | 2021 | Actual | 145 |
| Antibody-drug conjugate trial starts | 2020 | Actual | 101 |
| Alzheimer's disease drug trial starts | 2025 | Actual | 78 |
| Alzheimer's disease drug trial starts | 2024 | Actual | 71 |
| Alzheimer's disease drug trial starts | 2023 | Actual | 58 |
| Alzheimer's disease drug trial starts | 2022 | Actual | 81 |
| Alzheimer's disease drug trial starts | 2021 | Actual | 87 |
| Alzheimer's disease drug trial starts | 2020 | Actual | 66 |
Shared periods
Side by side
6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Antibody-drug conjugate trial starts | Alzheimer's disease drug trial starts |
|---|---|---|
| 2020 | 101 ClinicalTrials.gov | 66 ClinicalTrials.gov |
| 2021 | 145 ClinicalTrials.gov | 87 ClinicalTrials.gov |
| 2022 | 176 ClinicalTrials.gov | 81 ClinicalTrials.gov |
| 2023 | 233 ClinicalTrials.gov | 58 ClinicalTrials.gov |
| 2024 | 282 ClinicalTrials.gov | 71 ClinicalTrials.gov |
| 2025 | 349 ClinicalTrials.gov | 78 ClinicalTrials.gov |
Provenance
Where these numbers come from
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Alzheimer's disease drug trial starts
Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring